Amit Soni, MD, on Treating the First Patient With Hemophilia A Gene Therapy in the Real-World Setting
The medical director of the Center for Inherited Blood Disorders discussed the entrance of BioMarin’s val-rox into his center’s practice.
“This is a significant game changer. Gene therapy has been looked at for decades in hemophilia.”
On June 29, 2023, the FDA approved BioMarin’s valoctocogene roxaparvovec (val-rox) for the treatment of adults with severe hemophilia A, defined as congenital factor VIII (FVIII) deficiency with FVIII activity of less than 1 IU/dL, who do not have antibodies to adeno-associated virus serotype 5 (AAV5) according to an FDA-approved test.1 Val-rox is marketed in the United States under the name Roctavian and was the first gene therapy for hemophilia A to be approved in the US. Although many patients were treated in the clinical trials that the FDA based its approval decision on, it took some time for the gene therapy to make its way into standard use outside of the clinical trials. The first patient with hemophilia A, referred to as Maxwell L, was treated with val-rox in the real-world setting at the Center for Inherited Blood Disorders (CIBD) in Orange County California, in January 2024.2 Max’s treatment was deemed successful, although he remains under close monitoring to track the therapy’s effect on his disease.
Following up on this milestone event, CGTLive® reached out to Amit Soni, MD, the medical director of the CIBD, to ask about his team’s experience in administering val-rox to the first patient outside of clinical trials in the US. Soni gave some background information about val-rox, which is administered as a one-time treatment and expected to have a durable effect on the disease, emphasizing that it has dramatically altered the landscape of care for patients with hemophilia A, some of whom previously have had no choice but to rely on exogenous infusions of Factor VIII every week or even multiple times per week. Soni also discussed the difference between treating patients with val-rox in clinical trials as opposed to the real-world, and highlighted the fact that Max was able to receive the gene therapy in an outpatient setting at his regular treatment center for hemophilia A, with his regular care providers, rather than at a hospital.
